Two years ago, the Food and Drug Administration marked a big step forward in the way doctors think about cancer: It approved Merck’s Keytruda to treat tumors that appear anywhere in the body, but are marked with a specific genetic signature.

But identifying such cancers, called MSI-High, for “microsatellite instability-high,” required a biopsy of a tumor that had been surgically removed. In a paper published Monday, Guardant Health, a biotechnology company, published results saying it can tell whether a patient’s cancer is MSI-High with a type of blood test, also known as a liquid biopsy.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy